To compare international trends in mortality from cystic fibrosis. Design: Comparison of trends in median age at death using national mortality data. Setting: Data from 10 countries in North America, Europe, and Australasia. Participants: All persons registered as having died of cystic fibrosis in specified years from 1980 to 1994. Interventions: Comparison of relative odds of death at the international median age at death for the year of death between countries for two periods of time; from 1980 to 1987 (10 countries) and from 1980 to 1994 (7 countries). Measurements and results: The international median age at death increased from 8 years in 1974 to 21 years in 1994. Median age at death also increased within all countries, was consistently highest in the United States, and varied significantly by a factor of > twofold between countries. Women were significantly more likely to die at a younger age than the median age at death than men. Conclusions: Median age at death from cystic fibrosis is increasing, but our findings imply that clinically significant differences in survival with cystic fibrosis persist between countries.
D
uring the last 30 years, improvements in diagnosis and management of cystic fibrosis have resulted in a marked increase in life expectancy in this disease, [1] [2] [3] [4] [5] with the result that the majority of children born with cystic fibrosis now can expect to survive into adult life. Therefore, because the methods and accessibility of cystic fibrosis health-care provision vary substantially throughout the world, it is potentially informative to try to identify those countries providing the most effective health services for the disease. However, comparison of survival with cystic fibrosis between countries requires individual age and vital statistics data for all cases of cystic fibrosis born in all countries, and these data are not readily available at an international level in a standardized form.
Trends in survival with cystic fibrosis may, however, be inferred from trends in median age at death from this disease, 6 and this information can be obtained easily from routine national mortality data. We have therefore compared median age at death from cystic fibrosis in 10 countries for which we were able to obtain data, including countries in Europe, Australasia, and North America.
Materials and Methods

Data
Age-and sex-stratified mortality data for cystic fibrosis (International Classification Disease code 273.0 between 1974 and 1978, and 277.0 thereafter) were requested from the national offices of statistics for 16 countries in North America, Western Europe, and Australasia. In response to these requests, data were provided from the following 11 countries: Australia (for the years 1974 to 1994), Belgium (1974 Belgium ( to 1992 requested age-and sex-stratified all-cause mortality data from these countries and were provided with data in 5-year age bands suitable for comparison with the cystic fibrosis data from four of them (England and Wales, Scotland, Ireland, and New Zealand).
Statistical Analysis
Median ages at death from cystic fibrosis for each year in each country, estimated by interpolation when data were provided in 5-or 10-year age bands, was plotted against calendar year for visual comparison between countries. For statistical analysis of differences in median age at death between countries, we defined two data sets, one designed to include the greatest number of countries during the same period and comprising data from 10 countries for the period from 1980 to 1987, and one designed to make use of the most recent data available to us, comprising seven countries with data from 1980 to 1994. For each data set we estimated the overall international median age at death for each year, taking the median of the national median values to give equal weighting to data from all countries, irrespective of the number of deaths from cystic fibrosis in each country. The relative odds of death at an age above the annual international median age were then estimated for each country, and for women relative to men, by logistic regression, using a statistical software package (EGRET; SERC; Seattle, WA). When appropriate, we used estimates of logarithmic odds from these analyses to derive absolute proportions of the population in any country dying at an age above the international median age of death. We used the United States as the reference country because there were more deaths in absolute terms in the United States than in any other country. A similar approach was used to analyze trends in all-cause mortality for the four countries that provided suitable data, relating to the period from 1980 to 1994.
Statistical significance was inferred at the 5% level for national and sex differences when included as factored variables in the logistic regression analyses. Probability values for single odds ratios (ORs) for individual countries are given for information and without any correction for multiple comparisons.
Results
Median age at death from cystic fibrosis increased progressively as a function of time in all countries studied (Fig 1) , from an international median of 8 years in 1974 to 21 years in 1994. Women were significantly less likely to have died at an age above the annual median age at death than men (p Ͻ 0.001), with ORs of Ͻ 1 in all but two countries ( Table 1 ). All subsequent analyses were therefore performed with adjustment for sex.
For the more recent data set (1980 to 1994, seven countries), the sex-adjusted proportion of people dying from cystic fibrosis at an age above the international median age of death for their year of death differed significantly between countries (p Ͻ 0.001), being highest in the United States (54%) and lowest in Scotland (32%; OR relative to United States, 0.39; 95% confidence interval [CI], 0.30 to 0.52; p ϭ Ͻ 0.001). ORs for death at an age above the international median age at death are shown by country in Table 2 . Inclusion of data from the additional three countries available during the period from 1980 to 1987 made little difference to these rankings, the OR of death from cystic fibrosis above the international median age of death relative to the United States being lower in all other countries, with the lowest again being Scotland (OR, 0.42; 95% CI, 0.29 to 0.61; p Ͻ 0.001; Table 3 ).
Analysis of the odds of death at an age above the international median age for all-cause mortality also revealed significant differences between the countries for which data were available (p Ͻ 0.001), but the relative ranking of these countries was appreciably different from that for median age at death from cystic fibrosis ( Table 4) . The OR for all-cause mortality at an age above the international median age was highest in England and Wales, and lowest in New Zealand (OR, 0.74; 95% CI, 0.73 to 0.74; p Ͻ 0.001).
Discussion
In this study we have used international mortality data for cystic fibrosis to display the temporal trends in median age at death within countries and to compare the relative odds of death at an age above the median age between countries and between sexes. We have demonstrated that marked differences exist in median age at death between countries and have confirmed previous findings that women are less likely to die at an age above the median age than men. 3, 4, 7 We analyzed median age at death as our primary end point because this statistic can be obtained easily from routine national mortality data, and the alternative approach of using survival analysis requires assumptions to be made about the incidence of cystic fibrosis in different countries. Median age at death is an indirect marker of current mortality experience, and in a disease such as cystic fibrosis for which life expectancy is consistently increasing, median age at death will invariably underestimate median survival. However, in these circumstances, the temporal trend in median age at death will tend to follow the trend in survival and therefore provides a simple means of comparing the likely differences in survival between countries. An alternative and more robust approach would be to use standardized mortality ratios derived from individual survival data from complete and standardized patient registers, but these data are not readily available at an international level. One other disadvantage of the median age at death approach is that in smaller countries, such as Sweden and Ireland, in which the absolute number of deaths caused by cystic fibrosis is relatively low, annual estimates of median age at death are unstable. This effect can be seen clearly in the relatively marked variations between years within countries in Figure 1 .
Our finding that the median age at death was higher in men than in women has been reported in several previous studies. 3, 4, 7 Possible explanations for this include differences between sexes in access to medical services, difference in time to diagnosis, and a possible increased susceptibility to earlier Pseudomonas aeruginosa infection in women. 8 In light of this observation, all analyses of differences between countries were adjusted for sex differences.
Potential explanations for the observed international differences in median age at death from cystic fibrosis include differences in overall national sur- vival, in diagnosis and coding practice for cystic fibrosis, in socioeconomic status in people with cystic fibrosis, genotypic variation between countries, and access to appropriate health care. To obtain insight into overall differences in life expectancy between countries, we analyzed all-cause mortality data in the same way as the cystic fibrosis data and in a subgroup of four countries, and we found no obvious concordance with the rankings observed for cystic fibrosis. It is therefore relatively unlikely that differences in national life expectancy are a major determinant of the observed between-country differences in cystic fibrosis mortality. The validity, completeness, and comparability of diagnostic criteria for cystic fibrosis at the time of death in the different countries we have studied are not known, but it seems likely that, at least in recent years, these will be high in all of the countries involved. However, there are anomalies in the data that are difficult to explain, such as the relatively large number of deaths attributed to cystic fibrosis in Ireland compared with England and Wales, countries with a similar incidence of cystic fibrosis. Such a discrepancy may therefore have resulted from variations in diagnosis or coding in the mortality statistics.
Misclassification of cystic fibrosis deaths in infancy and early childhood could have a marked effect on median age at death in this data source, and we have previously suggested that misclassification and underdiagnosis may have accounted for the 20% discrepancy between the expected number of children born with cystic fibrosis in England and Wales in the early 1960s and the subsequent observed deaths in that cohort. 6 The extent of any such underdiagnosis is now likely to be considerably less, however, but could still contribute to differences in age at death between nations. Socioeconomic status, whether measured by parental occupation in the United Kingdom 6 or the presence of health insurance in the United States, 9 appears to be an important determinant of survival for people with cystic fibrosis. This effect is likely to be mediated in part by differences in access to specialized health-care services, inasmuch as, in the United Kingdom at least, attendance at specialized cystic fibrosis clinics, which confers benefit in terms of lung function and nutritional status, 10 is related to socioeconomic status. 11 It is therefore likely that some of the heterogeneity in survival with cystic fibrosis between countries arises from inequality in access to the highest quality health care. Further potential causes of differing trends in survival with cystic fibrosis internationally include differences in cystic fibrosis genotypes demonstrated in western Europe 12, 13 and variations in the distribution and virulence of pathogens in the different countries, causing differences in mortality. As yet, insufficient data are available to determine the contribution of these effects to international differences in survival. The alternative explanation for our observation of a greater than twofold difference in odds of survival beyond the median age between countries is that differences in health-care provision between countries are important. If this is the case, our study suggests that, at present, the best model of health care is that provided in the United States. This observation, together with the markedly worse prognosis in women, requires further investigation so that health-care services capable of delivering the highest chance of survival can be offered to all patients, regardless of sex or social advantage.
